15 Best S&P 500 Stocks That Don’t Pay Dividends

Published on December 13, 2022 at 10:39 am by Fatima Farooq in Hedge Funds, News

In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends.

The Standard and Poor’s 500 (S&P 500) is a stock market index that tracks the stock performance of pretty much the 500 largest companies listed on the major stock exchanges in the US. The index was subject to poorer performance over the last 12 months in light of various problems such as the geopolitical issues caused by the Russian invasion of Ukraine, widespread inflationary and recession concerns due to the Fed’s aggressive rate hike stance, and the bursting of the tech bubble. However, stocks listed on the S&P 500 saw broader gains in November and some market strategists are optimistic about December as well. Federal Reserve Chair Jerome Powell was also quoted as saying that the central bank will now slow its rate-hiking campaign, easing pressures on the market.

A few of the most famous names on the S&P 500 include companies such as Apple Inc. (NASDAQ:AAPL), Amazon.com, Inc. (NASDAQ:AMZN), and Microsoft Corporation (NASDAQ:MSFT). These being in the tech sector have consistently been among the best-performing sector on the index over the last decade. Such stocks helped the S&P 500 rise by about 5.4% at the close of November. The broader benchmark index ended up outperforming the smaller Nasdaq Composite index, which gained only 4.4% over the same period.

While many major companies on the index are also strong dividend payers, it is not a requisite condition for a company to be a dividend-payer for it to be an attractive investment choice. Many companies may choose to reinvest their proceeds from ongoing operations into their business models to retain their strong financial performance instead of paying out the same money to their shareholders. This opens larger avenues for a company’s individual growth in the long run.

We have compiled a list of the best S&P 500 stocks that don’t pay dividends, to recommend attractive stock picks for investors looking to invest in solid companies with long-term growth potential. Our rankings reflect the consensus opinion of 900+ hedge funds tracked by Insider Monkey.

Photo by Adam Nowakowski on Unsplash

Let’s now take a look at the 15 best S&P 500 stocks that don’t pay dividends.

Our Methodology

We have selected the best-performing S&P 500 stocks for our list below. They are ranked based on the number of hedge funds holding stakes in them, from the lowest to the highest. We have considered analyst ratings, core business strengths, revenue and net income growths, and more in our selection process.

Best S&P 500 Stocks That Don’t Pay Dividends

15. Teradata Corporation (NYSE:TDC)

Number of Hedge Fund Holders: 25

Teradata Corporation (NYSE:TDC) is a provider of a connected multi-cloud data platform for enterprise analytics. The company is based in San Diego, California.

Tyler Radke at Citigroup holds a Buy rating on Teradata Corporation (NYSE:TDC) shares of as November 11.

Teradata Corporation (NYSE:TDC) is expected to generate about $400 million of free cash flow by the end of 2022, giving the company an 11% free cash flow yield. The company’s strong free cash flow generation profile, balance sheet, and share buyback programs have reduced its outstanding share count by 8.2% over the past year

Teradata Corporation (NYSE:TDC) was found among the 13F holdings of 25 funds in the third quarter. Their total stake value was $340 million.

First Eagle Investment Management, an investment management firm, mentioned Teradata Corporation (NYSE:TDC) in its third-quarter 2021 investor letter. Here’s what the firm said:

“A longstanding participant in the data warehousing space, Teradata has been transitioning its focus from on-premises database management and analytics to the rapidly growing cloud-computing market. The company has delivered a series of impressive quarterly results, and markets appear to be taking notice of what we see as a sticky, high-margin, high-cash-generating business.”

14. Verisign, Inc. (NASDAQ:VRSN)

Number of Hedge Fund Holders: 37

Verisign, Inc. (NASDAQ:VRSN) is an information technology company. It provides domain name registry services and internet infrastructure that enables internet infrastructure for domain names globally.

Verisign, Inc. (NASDAQ:VRSN) saw its operating income margins increase significantly this year, standing at 10.8% year-over-year by this August. Revenue growth also stood at 6.8%. Finally, the company also delivered 63-65% of quarterly operating margins.

Berkshire Hathaway was the largest stakeholder in Verisign, Inc. (NASDAQ:VRSN) in the third quarter, holding 12.8 million shares worth $2.2 billion. In total, 37 funds were long the stock, with a total stake value of $4.3 billion.

Verisign, Inc. (NASDAQ:VRSN), like Apple Inc. (NASDAQ:AAPL), Amazon.com, Inc. (NASDAQ:AMZN), and Microsoft Corporation (NASDAQ:MSFT), is an S&P 5oo stock many investors are buying into this year.

13. Monster Beverage Corporation (NASDAQ:MNST)

Number of Hedge Fund Holders: 39

Monster Beverage Corporation (NASDAQ:MNST) is a soft drink company. It operates through its Monster Energy Drinks, Strategic Brands, and Other segments.

John Staszak at Argus holds a Buy rating on Monster Beverage Corporation (NASDAQ:MNST) shares as of November 29.

For the fiscal year ended 2021, Monster Beverage Corporation (NASDAQ:MNST) showed net sales growth of 20.5% year-over-year to $5.54 billion. The same rose by 15.2% year-over-year to $1.62 billion in the third quarter of 2022. The company’s gross margins stood at 51.3%, an improvement compared to the 47.1% margins in the previous quarter.

There were 39 hedge funds long Monster Beverage Corporation (NASDAQ:MNST) in the third quarter. Their total stake value was $1.9 billion.

Carillon Tower Advisers, an investment management company, mentioned Monster Beverage Corporation (NASDAQ:MNST) in its second-quarter 2022 investor letter. Here’s what the firm said:

“Monster Beverage Corporation (NASDAQ:MNST) develops and sells energy drinks and concentrates. The company’s shares outperformed, driven by an impressive earnings report highlighted by better than expected organic growth. Management also gave guidance that indicated a potential bottom in gross margins, as well as upcoming price increases that helped give investors confidence in its growth outlook.”

12. Waters Corporation (NYSE:WAT)

Number of Hedge Fund Holders: 41

Waters Corporation (NYSE:WAT) is a healthcare company. It provides analytical workflow solutions in Asia, the Americas, and Europe.

A Neutral rating was reiterated on Waters Corporation (NYSE:WAT) shares on November 2 by analyst Catherine Ramsey Schulte at Baird.

Management at Waters Corporation (NYSE:WAT) raised their guidance for 2022, now seeing a growth of 11-12% at the top line in constant currency terms. Analyst consensus estimates have valued the stock at 27.9x forward GAAP earnings and 27.3x forward non-GAAP EPS. It is thus expected that the company will outperform the benchmark in the future.

Waters Corporation (NYSE:WAT) had 41 hedge funds long its stock in the third quarter. Their total stake value was $1.8 billion.

Palm Capital, an investment management firm, mentioned Waters Corporation (NYSE:WAT) in its second-quarter 2021 investor letter. Here’s what the firm said:

“We also don’t invest in pharmaceutical companies. While revenue and profits are protected by patents, their future revenue depends on how quickly their drugs are copied once they fall off patent and the success of their R&D. Both are unpredictable.

Instead, we prefer to invest in companies that sell testing equipment and related consumables to the industry. Waters, for example, is a share that we have watched for years and would like to invest in at the right price. The company’s instruments are critical to the production and development of drugs and are the gold standard in the industry. Furthermore, they are often included in the patent applications of customers. This trust and reputation take years to build, resulting in high profit margins. At the same time, it also means that even when a drug of their customer falls off patent, the manufacturers of the generic version are likely to continue using the same instruments as these were already approved in the original application. So, the company’s revenues and profits are less dependent on patent cliffs or the success of R&D than those of pharmaceutical companies.”

11. Synopsys, Inc. (NASDAQ:SNPS)

Number of Hedge Fund Holders: 42

Synopsys, Inc. (NASDAQ:SNPS) is an information technology company based in Mountain View, California. The company provides electronic design automation software products used to design and test integrated circuits.

An Overweight rating was reiterated on Synopsys, Inc. (NASDAQ:SNPS) on December 1 by Peter Sazel at Atlantic Equities.

In the third quarter, Synopsys, Inc. (NASDAQ:SNPS) delivered revenues of $1.24 billion, compared to $1.05 billion in the year-ago period. This shows a year-over-year increase of 18%. The company’s EPS also increased by 16% year-over-year. Its balance sheet shows cash and equivalents of $1.4 billion and total debt of $669.1 million as of this October.

Synopsys, Inc. (NASDAQ:SNPS) had 42 hedge funds long its stock in the third quarter, with a total stake value of $1.9 billion.

Carillon Tower Advisers, an investment management firm, mentioned Synopsys, Inc. (NASDAQ:SNPS) in its fourth-quarter 2021 investor letter. Here’s what the firm said:

“Synopsys is a semiconductor software company that supplies electronic design automation solutions to the global electronics market. The firm’s shares outperformed in the quarter after management outlined a longer-term vision at the company’s analyst day and suggested a higher level of growth going forward than it has achieved in the previous few years. Synopsys is becoming a key supplier of leading-edge semiconductor designs that are getting increasingly more difficult for chip companies to build on their own. On top of accelerating topline growth, the company also posts healthy profits and robust cash flow generation.”

10. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 43

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotech company. It develops and commercializes medicines to treat a range of diseases across the globe.

Brian Abrahams at RBC Capital holds a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares as of November 9.

In the third quarter, Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) Eylea medicine net sales grew by 11% year-over-year to $1.63 billion in the US. Another product, Dupixent, generated net sales that grew by 40% year-over-year to $2.33 billion. The company’s share of antibody profits also rose by 42% year-over-year to $551 million.

There were 43 hedge funds long Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter. Their total stake value was $1.3 billion.

Bronte Capital, an investment management company, mentioned Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its third-quarter 2022 investor letter. Here’s what the firm said:

“There have been some bright spots in our long book. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a major position and a stock we wrote up in our June 2021 letter, has been one of the best performing stocks in the S&P 500 this year. Alas it has not been enough to offset some of our weaker stocks, let alone our overweight exposure to the UK (and Europe) which have suffered from both stock and currency weakness. We do not think we are bad at picking stocks on the long side and hope – reasonably we think – for better relative results in the future. Prior to COVID, our longs were markedly better than the index. Unfortunately, if you look at our long book this quarter and since the onset of the COVID pandemic, there is scant evidence that we have added any value by picking stocks to go long.”

9. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Holders: 70

Biogen Inc. (NASDAQ:BIIB) is a healthcare company. It develops and delivers therapies to treat neurological and neurodegenerative diseases.

Salim Syed at Mizuho holds a Buy rating on Biogen Inc. (NASDAQ:BIIB) shares as of November 30.

Analysts forecast that Biogen Inc.’s (NASDAQ:BIIB) Lecanemab drug will see total peak sales of $14 billion with the company sharing 50% of the profits. They also forecast a $17 EPS for the company in 2022.

Out of 920 hedge funds tracked in the third quarter, 70 funds were long Biogen Inc. (NASDAQ:BIIB), with a total stake value of $3.7 billion.

ClearBridge Investments, an investment management company, mentioned Biogen Inc. (NASDAQ:BIIB) in its third-quarter 2022 investor letter. Here’s what the firm said:

“Biogen Inc. (NASDAQ:BIIB) was the leading contributor among several biopharma names, boosted by positive, pivotal clinical data for its next-generation Alzheimer’s treatment Lecanemab. In a pivotal trial, the drug proved safe and efficacious in slowing progression of Alzheimer’s disease.”

8. Tesla, Inc. (NASDAQ:TSLA)

Number of Hedge Fund Holders: 88

Tesla, Inc. (NASDAQ:TSLA) is an electric vehicle manufacturing company, based in Austin, Texas. The company operates through its Automotive and Energy Generation and Storage segments.

Alexander Potter at Piper Sandler holds an Overweight rating on Tesla, Inc. (NASDAQ:TSLA) as of December 8. The analyst also placed a $340 price target on the stock.

Tesla, Inc. (NASDAQ:TSLA) is a stock expected to deliver strong growth across all its key financial metrics over the next five years. Consensus data from S&P Capital IQ estimates that the company’s top line will grow by a 30% CAGR from $53.8 billion in 2021 to $201.7 billion in 2026. The company’s normalized net income and free cash flow are also expected to rise by CAGRs of 29% and 45% to $26.8 billion and $32.5 billion, respectively.

There were 88 funds long Tesla, Inc. (NASDAQ:TSLA) in the third quarter, with a total stake value of $7.4 billion.

7. Advanced Micro Devices, Inc. (NASDAQ:AMD)

Number of Hedge Fund Holders: 89

Advanced Micro Devices, Inc. (NASDAQ:AMD) is another information technology company on our list. The company operates through its Computing and Graphics and Enterprise, Embedded and Semi-Custom segments.

Chris Caso at Credit Suisse initiated coverage of Advanced Micro Devices, Inc. (NASDAQ:AMD) on November 15 with an Outperform rating.

In the third quarter, Advanced Micro Devices, Inc. (NASDAQ:AMD) reported revenues of $5.6 billion, representing an increase of 29% year-over-year. The company’s Data Center segment generated solid growth. Its revenue also increase by 45% year-over-year to $1.6 billion.

Advanced Micro Devices, Inc. (NASDAQ:AMD) had 89 hedge funds long its stock in the third quarter, with a total stake value of $4.9 billion.

6. Netflix, Inc. (NASDAQ:NFLX)

Number of Hedge Fund Holders: 115

Netflix, Inc. (NASDAQ:NFLX) is a communication services stock. It offers TV series, documentaries, feature films, and mobile games.

BofA’s Jessica Reif Ehrlich reinstated coverage of Netflix, Inc. (NASDAQ:NFLX) with a Buy rating on November 15.

Netflix, Inc. (NASDAQ:NFLX) is currently a global leader in the streaming service space. The company boasts over 223 million paid memberships in over 190 countries. As of this November, the company saw its streaming membership rise by over 5%.

We saw 115 hedge funds long Netflix, Inc. (NASDAQ:NFLX) in the third quarter with a total stake value of $6.7 billion.

Harding Loevner, an asset management company, mentioned Netflix, Inc. (NASDAQ:NFLX) in its third-quarter 2022 investor letter. Here’s what the firm said:

“Netflix, Inc. (NASDAQ:NFLX) mustered a modest recovery as the market Allocation Effect: 0.3 mulled the potential of its new lower-priced ad-supported subscription model to drive revenue growth and reduce its dependency on continued heavy investment in content to attract and retain viewers.”

Click to continue reading and see the 5 Best S&P 500 Stocks That Don’t Pay Dividends.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on December 13, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up